The association of serum chemerin levels with retinopathy in patients with type 2 diabetes mellitus

Serum chemerin levels in diabetic retinopathy




Chemerin, diabetic retinopathy, type 2 diabetes mellitus


Objective: The aim of this study is to investigate serum chemerin levels in patients with Type 2 diabetes mellitus (T2DM).

Methods: The present study included 57 patients with T2DM and 20 healthy individuals. The T2DM patients were divided into 3 groups including non-retinopathy, non-proliferative retinopathy and proliferative retinopathy. Body Mass Index, HbA1c, fasting blood glucose, central macular thickness of the participants were recorded.

Results:  There was not any significant difference between chemerin levels of the patients and the control group (0.93±1.27 µg/ml vs. 1.27±1.11 µg/ml; p=0.08). No significant difference was detected between the patients with retinopathy and the control group for chemerin levels (p=0.13).

Conclusion: The present study detected that there was not any significant difference between T2DM patients and the control group for serum chemerin levels. The reason for that may be due to the fact that serum chemerin levels are affected many other factors.


Shi GJ, Shi GR, Zhou JY, Zhang WJ, Gao CY, Jiang YP et al. Involvement of growth factors in diabetes mellitus and its complications: a general review. Biomed Pharmacother. 2018;101:510-27.

Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med. 2003;96:266-72.

Tielsch JM, Sommer A, Witt K, Katz J, Royall RM. Blindness and visual impairment in an American urban population: the Baltimore Eye Survey. Arch Ophthalmol. 1990;108:286-90.

Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.

Pusparajah P, Lee LH, Abdul Kadir K. Molecular markers of diabetic retinopathy: potential screening tool of the future? Front Physiol. 2016;7:200.

Du J, Li R, Xu L, Ma R, Liu J, Cheng J, et al. Increased Serum Chemerin Levels in Diabetic Retinopathy of Type 2 Diabetic Patients. Curr Eye Res. 2016;41:114-20.

Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007;282:28175-88.

Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-94.

Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun. 2010;391:1762-68.

Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost. 2000;26:529–37.

Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009;94:3085-8.

Tahir NT, Falih IQ, Husaini FK, Zeghair SA. Study The Effect Of Chemerin Level In Type II Diabetic Patients With And Without Retinopathy. Systematic Reviews in Pharmacy. 2020;11:1856-63.

Halawa MR, Abdullah AA, Ibrahim NA, El-Sabawy AM. Chemerin is associated with diabetic retinopathy in type 2 diabetes. Egypt J Obes Diabetes Endocrinol. 2018;4:23-9.

Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond). 2005;109:143-59.

Li J, Hu WC, Song H, Lin JN, Tang X. Increased vitreous chemerin levels are associated with proliferative diabetic retinopathy. Ophthalmologica. 2016;236:61-6.

Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010;185:3728–39.

Yang M, Yang G, Dong J, Liu Y, Zong H, Liu, H et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. 2010;58:883–6.

Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299:506–15.

Yoshimura T, Oppenheim JJ. Chemerin reveals ist chimeric nature. J Exp Med. 2008;205:2187-90.

Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010;95:2476–85.

Er LK, Wu S, Hsu LA, Teng MS, Sun YC, Ko YL. Pleiotropic Associations of RARRES2 Gene Variants and Circulating Chemerin Levels: Potential Roles of Chemerin Involved in the Metabolic and Inflammation-Related Diseases. Mediators Inflamm. 2018;4670521.

Mussig K, Staiger H, Machicao F, Thamer C, Machann J, Schick F, et al. RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: A comparative magnetic resonance imaging study. Metabolism. 2009;58:519–24.

Tonjes A, Scholz M, Breitfeld J, Marzi C, Grallert H, Gross A, et al. Genome wide meta-analysis highlights the role of genetic variation in RARRES2 in the regulation of circulating serum chemerin. PloS Genet. 2014;10:e1004854.

Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, et al. Diabetic retinopathy in a multiethnic cohort in the United States. Am J Ophthalmol. 2006;141:446-55.

Zhao L, Yamaguchi Y, Shen WJ, Morser J, Leung LLK. Dynamic and tissue-specific proteolytic processing of chemerin in obese mice. PloS One. 2018;13:e0202780.

Chang SS, Eisenberg D, Zhao L, Adams C, Leib R, Morser J, et al. Chemerin activation in human obesity. Obesity. 2016;24:1522–9.




How to Cite

Duran, M. ., Karabulut, A., & Şahin, T. . (2023). The association of serum chemerin levels with retinopathy in patients with type 2 diabetes mellitus: Serum chemerin levels in diabetic retinopathy. The Injector, 2(2), 113–119.



Original Article